Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 5:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–71 of 71 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Exenatide twice daily (BID) Clear all
Completed Phase 4 Interventional Results available

The Vascular Effects of Exenatide Versus Metformin in Patients With Pre-Diabetes

NCT00546728
View directory record Official record
Conditions
Impaired Glucose Tolerance
Interventions
Exenatide, Metformin
Drug
Lead sponsor
St. Paul Heart Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Saint Louis Park, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 8, 2013 · Synced Oct 8, 2026, 5:28 AM EDT
Completed Phase 3 Interventional Results available

Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)

NCT00308139
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide, long acting release, exenatide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
16 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
24
States / cities
Encino, California • La Jolla, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2015 · Synced Oct 8, 2026, 5:28 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Exenatide in Obese Patients With Accelerated Gastric Emptying

NCT02160990
View directory record Official record
Conditions
Obesity
Interventions
Exenatide, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 9, 2016 · Synced Oct 8, 2026, 5:28 AM EDT
Completed Phase 4 Interventional Results available

Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease

NCT01006889
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus
Interventions
Exenatide
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2016 · Synced Oct 8, 2026, 5:28 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes

NCT01652716
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Exenatide once weekly suspension, Exenatide twice daily
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
58
States / cities
Muscle Shoals, Alabama • Mesa, Arizona • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Oct 8, 2026, 5:28 AM EDT
Completed Not applicable Interventional Results available

Continuous Glucose Monitoring Evaluation of Exenatide Twice Daily Versus Insulin Glargine

NCT01089569
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Exenatide, Insulin Glargine
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Oct 8, 2026, 5:28 AM EDT
Completed Phase 3 Interventional

An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes Mellitus

NCT01876849
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
30 Years to 75 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Renton, Washington
Source: ClinicalTrials.gov public record
Updated Feb 24, 2015 · Synced Oct 8, 2026, 5:28 AM EDT
Completed Phase 2 Interventional

Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus

NCT00085969
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo 0.04 mL twice daily, Placebo 0.04 mL once daily, Placebo 0.08 mL once daily, B - Exenatide 10 mcg twice daily, C - Exenatide 10 mcg once daily, Exenatide 20 mcg once daily
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
23
States / cities
La Jolla, California • San Diego, California • Washington D.C., District of Columbia + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Oct 8, 2026, 5:28 AM EDT
Terminated Phase 4 Interventional Results available

An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects

NCT02793154
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Exenatide, Albiglutide
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Louisville, Kentucky • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2020 · Synced Oct 8, 2026, 5:28 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Exenatide as Monotherapy

NCT00381342
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide, placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Idaho Falls, Idaho • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Oct 8, 2026, 5:28 AM EDT
Completed Phase 3 Interventional Results available

A Study in Participants With Type 2 Diabetes Mellitus

NCT01064687
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2189265, Exenatide, Placebo, Metformin, Pioglitazone
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
978 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
78
States / cities
Goodyear, Arizona • Phoenix, Arizona • Cathedral City, California + 75 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Oct 8, 2026, 5:28 AM EDT
Completed Phase 3 Interventional Results available

An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus

NCT00135330
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
exenatide, rosiglitazone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
19
States / cities
Phoenix, Arizona • San Francisco, California • Jacksonville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 8, 2026, 5:28 AM EDT
Completed Not applicable Interventional Results available

Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass

NCT00775684
View directory record Official record
Conditions
Pre-diabetes, Type 2 Diabetes
Interventions
Exenatide, Sitagliptin, Glimepiride
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
3
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 7, 2022 · Synced Oct 8, 2026, 5:28 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

How Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2 Diabetics

NCT00667732
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
exenatide, placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
30 Years to 70 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Rochester, Minnesota • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 6, 2013 · Synced Oct 8, 2026, 5:28 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women

NCT00456885
View directory record Official record
Conditions
Obesity, Impaired Glucose Tolerance
Interventions
exenatide, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
25 Years to 60 Years · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 8, 2026, 5:28 AM EDT
Completed No phase listed Observational

Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes Taking Twice-Daily Exenatide or Once-Weekly Exenatide

NCT00803920
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Not listed
Lead sponsor
HealthPartners Institute
Other
Eligibility
16 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Oct 8, 2026, 5:28 AM EDT
Completed Phase 3 Interventional

A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.

NCT00717457
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
exenatide, taspoglutide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
87
States / cities
Haleyville, Alabama • Mobile, Alabama • Montgomery, Alabama + 78 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 8, 2026, 5:28 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Role of Exenatide in NASH-a Pilot Study

NCT00650546
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease
Interventions
Exenatide
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 99 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
3
States / cities
Indianapolis, Indiana • Kansas City, Missouri • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 8, 2026, 5:28 AM EDT
Completed Phase 4 Interventional Results available

Effect of Exenatide on Liver and Heart Fat and Inflammation

NCT01951651
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Exenatide, Glipizide
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
30 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Oct 8, 2026, 5:28 AM EDT
Completed Not applicable Interventional Results available

Effects of Exenatide on Overweight Adolescents With Prader-Willi Syndrome

NCT01444898
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
Exenatide
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
13 Years to 20 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Oct 8, 2026, 5:28 AM EDT
Completed Phase 2 Interventional

Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus

NCT00044694
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
Placebo 0.01 mL, Placebo 0.02 mL, Placebo 0.03 mL, Placebo 0.04 mL, AC2993 2.5 mcg, AC2993 5.0 mcg, AC2993 7.5 mcg, AC2993 10.0 mcg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
33
States / cities
Birmingham, Alabama • Anaheim, California • Bellflower, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2015 · Synced Oct 8, 2026, 5:28 AM EDT
Completed Phase 4 Interventional Results available

Effect Of Exenatide Treatment on Liver Fat Content in Patients With Diabetes

NCT01432405
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Exenatide, Pioglitazone
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
30 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 12, 2016 · Synced Oct 8, 2026, 5:28 AM EDT
Completed Not applicable Interventional Results available

Impact of Exenatide on Sleep in Type 2 Diabetes

NCT01136798
View directory record Official record
Conditions
Type 2 Diabetes, Sleep Disordered Breathing
Interventions
Exenatide, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Oct 8, 2026, 5:28 AM EDT